$2.21
arrow_drop_up3.51%Key Stats | |
---|---|
Open | $2.14 |
Prev. Close | $2.13 |
EPS | -0.40 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $86.04M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.13 | 2.24 |
52 Week Range | 0.65 | 4.00 |
Ratios | |
---|---|
EPS | -0.40 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Files 2023 Annual Report on Form 20-F
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer